FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
25/06/2026
Voltar para busca
Dado oficial do USPTO
ALCHEMAB
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
ALCHEMAB
ST13
US500000079403954Classe
5, 9, 42, 44
Pedido
79403954
Registro
8026498
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
33
Atualização mais recente
25/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 9, 42, 44
Data de depósito
03/07/2024
Data de registro
18/11/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
18/11/2025
Última transação
25/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
London, GB
Examinador
MEYERS, MORGAN LAURA
Unidade examinadora
L40
Localização atual
TMEG LAW OFFICE 104
Titulares e representantes
Titulares
Alchemab Therapeutics Ltd
Alchemab Therapeutics Ltd
Representantes
James M. Theo Dinsmore & Shohl LLP
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations incorporating antibodies for the treatment of neurological and neurodegenerative diseases and disordersmetabolic diseases and disordersimmunological diseases and disordersoncological diseases and disordersAmyotrophic Lateral Sclerosis (ALS)muscle atrophyParkinson's disease and Alzheimer's disease; pharmaceutical preparations incorporating antibody technology for the treatment of neurological and neurodegenerative diseases and disordersmetabolic diseases and disordersimmunological diseases and disordersoncological diseases and disordersAmyotrophic Lateral Sclerosis (ALS)muscle atrophyParkinson's disease and Alzheimer's disease; chemical preparations for medical and pharmaceutical purposes incorporating antibodies for the treatment of neurological and neurodegenerative diseases and disordersmetabolic diseases and disordersimmunological diseases and disordersoncological diseases and disordersAmyotrophic Lateral Sclerosis (ALS)muscle atrophyParkinson's disease and Alzheimer's disease; Chemical preparations for medical and pharmaceutical purposes incorporating antibody technology for the treatment of neurological and neurodegenerative diseases and disordersmetabolic diseases and disordersimmunological diseases and disordersoncological diseases and disordersAmyotrophic Lateral Sclerosis (ALS)muscle atrophyParkinson's disease and Alzheimer's disease; antibodies for medical purposes; diagnostic preparations involving the testing and identification of antibodies for medical purposes; diagnostic preparations involving the testing of antibodies for medical purposes; diagnostic preparations involving the identification of antibodies for medical purposes.
Classe 9
Downloadable software for the testing of antibodies; downloadable software for the identification of antibodies; downloadable software for use in development of pharmaceutical preparations incorporating antibodies; downloadable software for use in development of pharmaceutical preparations incorporating antibody technology.
Classe 42
Research and development services in the field of antibodies and antibody technology; drug development and discovery services in relation to pharmaceutical preparations incorporating antibodies and antibody technology; antibody discovery services in the nature of drug discovery services; development and testing of computing methodsalgorithms and software for the testing and identification of antibodies; development and testing of computing methodsalgorithms and software in the field of antibody technology; development and testing of computing methodsalgorithms and software for use in or relating to the development of pharmaceutical preparations incorporating antibodies and antibody technology; informationadvisory and consultancy services in relation to all of the aforesaid.
Classe 44
Medical diagnostic services involving the testing of antibodies for medical purposes; medical diagnostic services involving the identification of antibodies for medical purposes; medical testinganalysis and diagnostic services in the field of antibodies; informationadvisory and consultancy services in relation to all of the aforesaid.
Publicações
Histórico de despachos e eventos da marca no USPTO.
33 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/06/2026
FIMP
FINAL DISPOSITION PROCESSED
04/06/2026
NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
14/04/2026
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
23/03/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/03/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
19/02/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
18/02/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/02/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
04/02/2026
ES7R
TEAS SECTION 7 REQUEST RECEIVED
09/12/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
18/11/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
18/11/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
30/09/2025
PUBO
PUBLISHED FOR OPPOSITION
30/09/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
24/09/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
28/08/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
28/08/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
28/08/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
28/08/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
28/08/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/08/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/08/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/08/2025
RFNT
REFUSAL PROCESSED BY IB
22/03/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/03/2025
RFRR
REFUSAL PROCESSED BY MPU
04/03/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
16/01/2025
CNRT
NON-FINAL ACTION WRITTEN
15/01/2025
DOCK
ASSIGNED TO EXAMINER
28/12/2024
MAFR
APPLICATION FILING RECEIPT MAILED
09/09/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/09/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/09/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ALCHEMAB ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.